Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 9/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7113237 | 0.89 | ADRB3 (0.45) | ADRB3KMT2AMEN1GAASMN1; SMN2 | |
| SCHEMBL7114763 | 0.83 | ADRB3 (0.64) | ADRB3ADRB2 | |
| SCHEMBL2452164 | 0.83 | CYP19A1 (0.43) | ADRB3SMN1; SMN2CYP19A1ADRB2TRPV1 | |
| SCHEMBL14090675 | 0.83 | CYP19A1 (0.43) | ADRB3SMN1; SMN2CYP19A1ADRB2TRPV1 | |
| SCHEMBL8817465 | 0.83 | CYP19A1 (0.43) | ADRB3SMN1; SMN2CYP19A1ADRB2TRPV1 | |
| SCHEMBL2454673 | 0.83 | CYP19A1 (0.43) | ADRB3SMN1; SMN2CYP19A1ADRB2TRPV1 | |
| SCHEMBL2009303 | 0.82 | ADRB2 (0.44) | ADRB3KMT2AMEN1GAASMN1; SMN2 | |
| SCHEMBL2009305 | 0.82 | ADRB2 (0.44) | ADRB3KMT2AMEN1GAASMN1; SMN2 | |
| SCHEMBL2009306 | 0.82 | ADRB2 (0.44) | ADRB3KMT2AMEN1GAASMN1; SMN2 | |
| SCHEMBL5563548 | 0.81 | ADRB2 (0.47) | ADRB3CYP19A1ADRB2TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6569873-B2 | Treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia, atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination | WYETH | 2003-05-27 | — | — | US | disclosed |
| US-20030055079-A1 | Azolidines as beta-3 adrenergic receptor agonists | WYETH | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055079-A1 | Azolidines as beta-3 adrenergic receptor agonists | GPR119, ADRB1, ADRB3 | ADRB3 3/4885KMT2A 2903/4885MEN1 1800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.